cd38 inhibitor and 5-amino-1mq synergy nad+ The Pharmacology of CD38/NADase: An emerging target for cancer aging diseases Evolving roles of CD38 metabolism
Evolving roles of CD38 metabolism in solid tumour microenvironment British Journal of Cancer Targeting NAD+ Synthesis to Potentiate CD38 Based Immunotherapy of Multiple Myeloma ScienceDirect CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions PMC Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38: Implications for Cellular NAD+ Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome PMC CD38 Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+ Lowering Agents
Pay in 4 interest-free payments of $7.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7




